Rhumbline Advisers Ultragenyx Pharmaceutical Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 103,626 shares of RARE stock, worth $3.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
103,626
Previous 104,793
1.11%
Holding current value
$3.2 Million
Previous $3.79 Million
0.71%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding RARE
# of Institutions
365Shares Held
88.1MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.2MShares$315 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$173 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$122 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$89.1 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.77MShares$85.6 Million1.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.16B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...